South Texas Accelerated Research Therapeutics

San Antonio’s cancer genomics partnership launches

Wednesday, November 4, 2015

The San Antonio 1000 Cancer Genomes Project (SA1kCGP), Shanghai-based WuXi NextCODE and South Texas Accelerated Research Therapeutics (START) have partnered to enable San Antonio’s pioneering citywide cancer genomics effort to contribute directly to improving the clinical treatment of cancer around the globe. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create the basis for the resource: tumor samples from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, brain cancers, collected at the time of diagnosis.

[Read More]

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

[Read More]